Vaccinations to Prevent Infections in Adult Individuals With CKD and After Kidney Transplantation: A Review
Abstract
Patients with chronic kidney disease (CKD), especially those undergoing dialysis, are at high risk of infections that lead to hospitalizations, morbidity, and mortality. Influenza, pneumococcal pneumonia, and respiratory syncytial virus infections account for a significant proportion of typical infectious complications and are preventable by vaccination. The immune system is weakened in CKD, reducing vaccination efficacy. Additionally, some patients with CKD receive immunosuppressive medications. The reduced seroreactivity to various vaccines must be considered when selecting vaccines, vaccine doses, and schedules for patients with CKD. Vaccinations are generally safe in CKD and should be widely used in accordance with public health recommendations to reduce morbidity. Immunosuppression after kidney transplant further impairs vaccination responses. Nevertheless, vaccinations can still be effective and provide protection in a relevant number of patients. Patients who have received transplants should generally not receive live vaccines because of the risk of vaccine-induced complications. Vaccination is usually recommended 6 months after transplant, when immunosuppression is less intense than in the early months. This approach may conflict with seasonal vaccinations, which are often omitted. Data show that at least the influenza vaccination can be administered as early as 4 weeks after transplant without additional risk. In all patients with CKD or posttransplant status, omitting recommended vaccinations is a missed opportunity to prevent relevant infectious complications.
Fields of Study & Subjects
Renal Transplantation Outcomes and Treatments
Cytomegalovirus and herpesvirus research
Biological Research and Disease Studies
Publication details
- Journal / source
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Volume
- 87
- Issue
- 6
- Pages
- 841–851
- Publication date
- 25 February 2026
- Language
- EN